Compare FDC with Similar Stocks
Dashboard
Poor long term growth as Operating profit has grown by an annual rate -4.35% of over the last 5 years
Negative results in Dec 25
With ROE of 9.3, it has a Expensive valuation with a 2.4 Price to Book Value
Falling Participation by Institutional Investors
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
INR 5,882 Cr (Small Cap)
25.00
33
1.36%
-0.17
9.27%
2.46
Total Returns (Price + Dividend) 
Latest dividend: 5 per share ex-dividend date: Feb-11-2026
Risk Adjusted Returns v/s 
Returns Beta
News

FDC Ltd is Rated Strong Sell by MarketsMOJO
FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 07 March 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
FDC Ltd Stock Falls to 52-Week Low Amidst Continued Downtrend
FDC Ltd’s share price declined sharply to a fresh 52-week low of Rs.330.05 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s shares have been under pressure for several sessions, reflecting a combination of subdued financial performance and valuation concerns.
Read full news article
FDC Ltd Stock Falls to 52-Week Low Amidst Continued Downtrend
FDC Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low of Rs.355.05 today, marking a significant decline amid a sustained downward trend. The stock has underperformed both its sector and the broader market, reflecting ongoing concerns about its financial performance and valuation metrics.
Read full news article Announcements 
FDC Limited - Clarification - Financial Results
14-Nov-2019 | Source : NSEFDC Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
FDC Limited - Updates
18-Oct-2019 | Source : NSEFDC Limited has informed the Exchange regarding 'Acquisition of Registered Trademark/ Brand "ENTEROPLUS" from GlaxoSmithKline Pharmaceuticals Limited (GSK)'.
FDC Limited - Updates
16-Oct-2019 | Source : NSEFDC Limited has informed the Exchange regarding 'Certificate in terms of Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 ( said regulations ) on behalf of FDC Limited ( the Company ) for the quarter ended on September 30, 2019'.'.
Corporate Actions 
No Upcoming Board Meetings
FDC Ltd has declared 500% dividend, ex-date: 11 Feb 26
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 9 Schemes (6.21%)
Held by 92 FIIs (2.32%)
Nomita R Chandavarkar (22.67%)
Icici Prudential Smallcap Fund (2.76%)
16.97%
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
QoQ Growth in quarter ended Dec 2025 is -1.76% vs -27.05% in Sep 2025
QoQ Growth in quarter ended Dec 2025 is -0.25% vs -76.62% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -2.66% vs 12.65% in Sep 2024
Growth in half year ended Sep 2025 is -21.65% vs 6.33% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is -1.86% vs 9.14% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -21.96% vs -11.90% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 8.50% vs 8.92% in Mar 2024
YoY Growth in year ended Mar 2025 is -12.59% vs 57.30% in Mar 2024






